Delivery Order SPE2DB22D3501-SPE2DB25FXH20
Award Date 9/12/25
Potential Completion Date 9/15/25
Potential Value $3.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,684.96 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is structured under a firm fixed price contract type with no set-aside designation, indicating competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $114,722.94 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 ml syringes). This competitively awarded, firm fixed-price delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,948.68 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a procurement of hepatitis B vaccine supplies to support federal medical requirements. The order is being fulfilled from AmerisourceBergen's place of performance in...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $109,748.87 to AmerisourceBergen Drug Corp for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award based on open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. This...
- The U.S. Department of Defense's Medical Supply Chain awarded a $9,236.60 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes. This competitively awarded, firm fixed-price contract represents a single delivery order fulfillment without set-aside provisions. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is a...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...